“Our battle with COVID-19 shows just how vital pharmaceutical innovation is to our health and survival, and we cannot afford to limit companies’ ability to develop lifesaving treatments for this or future medical crises,” said NAM President and CEO Jay Timmons.
“Regardless of intentions, an international pricing index that ties any portion of our system to a foreign government-run health care system is an abdication of free market principles, and importing drugs from Canada poses a serious health risk, especially considering the counterfeiting challenges we already face. Manufacturers of all sectors are committed to lowering health care costs, but the answer is to pursue market-based solutions that deliver choice and flexibility.”
To view the ad, click here.
